The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Post‐tuberculosis lung abnormality (PTLA) is the most common risk factor for chronic pulmonary aspergillosis (CPA), and 14%–25% of the subjects with PTLA develop CPA. The pathogenesis and the host immune response in subjects with PTLA who develop CPA need to be better understood.
Methods
We prospectively compared the innate and adaptive immune responses mounted by patients of PTLA with...
Background
Post‐tuberculosis lung abnormality (PTLA) is the most common risk factor for developing chronic pulmonary aspergillosis (CPA). However, the prevalence and incidence of CPA in PTLA patients in India remain unknown.
Objectives
We aimed to ascertain the incidence and prevalence of CPA in subjects with PTLA.
Methods
We identified a cohort of pulmonary tuberculosis who completed anti‐tuberculosis...
Background
Aspergillus fumigatus‐specific IgG estimation is crucial for diagnosing allergic bronchopulmonary aspergillosis (ABPA). A point‐of‐care LDBio immunochromatographic lateral flow assay (LFA) had 0%–90% sensitivity to detect IgG/IgM antibodies against A. fumigatus.
Objective
To assess the accuracy of LDBio‐LFA in diagnosing ABPA, using the modified ISHAM‐ABPA working group criteria as the...
Background
The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown.
Methods
In this open‐label trial, we randomized PM subjects to receive either intravenous liposomal amphotericin B (control arm, 3–5 mg/kg/day) alone or along with nebulized amphotericin B deoxycholate (NAB, 10 mg twice a day, every alternate day). The primary outcomes were: (1) overall response...
Background
Whether chronic pulmonary aspergillosis (CPA) has different immunophenotypes remains unknown.
Objective
To identify different CPA immunophenotypes using cluster analysis.
Methods
We used a subject‐centred multivariate clustering approach without prior assumptions to identify CPA phenotypes. We retrospectively included the data of treatment‐naïve subjects with CPA and excluded subjects...
Background
Whether off‐site evaluation of slides by a cytologist viewing the images shared by WhatsApp improves the on‐site evaluation by a pulmonologist (P‐ROSE) remains unknown. This study's objective was to compare the sensitivity of P‐ROSE and WHOSE for adequacy and diagnosis of cytology specimens obtained by endobronchial ultrasound (EBUS)‐guided transbronchial needle aspiration (TBNA).
Materials...
Background
Isolated tracheobronchial mucormycosis (ITBM) is an uncommonly reported entity. Herein, we report a case of ITBM following coronavirus disease 2019 (COVID‐19) and perform a systematic review of the literature.
Case description and systematic review
A 45‐year‐old gentleman with poorly controlled diabetes mellitus presented with cough, streaky haemoptysis, and hoarseness of voice 2 weeks...
Background
The diagnostic accuracy of immunoassays versus immunoprecipitation methods for detecting A.fumigatus‐specific IgG in patients with allergic bronchopulmonary aspergillosis (ABPA) complicating asthma remains unclear.
Methods
We performed a systematic review to identify studies describing both the methods in the same ABPA subjects. We assessed study quality using the QUADAS‐2 tool. We derived...
Background
The prevalence and outcomes of allergic bronchopulmonary aspergillosis (ABPA) in the elderly remain unknown.
Methods
We reviewed our database to identify the proportion of subjects diagnosed with ABPA at ≥60 years of age (ABPA‐elderly). We compared the clinical features, treatment and outcomes of ABPA‐elderly versus the non‐elderly (ABPA diagnosed at <60 years of age).
Results
Between...
Background
Oral itraconazole and voriconazole are currently recommended in the initial management of chronic pulmonary aspergillosis (CPA). However, only a few studies have compared outcomes with different anti‐fungal agents (AFAs) in treating CPA. Herein, we perform a network meta‐analysis comparing the efficacy of different AFAs in CPA.
Methods
We searched the PubMed and EmBase databases to identify...